Eli Lilly (LLY) Stock Price: Why It Increased Over 1.3% Today

By Amit Chowdhry ● Jun 7, 2022
  • The stock price of Eli Lilly And Co (NYSE: LLY) increased by over 1.3% during intraday trading today. This is why.

The stock price of Eli Lilly And Co (NYSE: LLY) increased by over 1.3% during intraday trading today. Investors are responding positively to Eli Lilly announcing topline results from one-year analyses of the efficacy and safety of lebrikizumab, the company’s investigational IL-13 inhibitor for the treatment of patients with moderate-to-severe atopic dermatitis (AD). 

The new findings from the Phase 3 clinical trials (ADvocate 1 and 2) showed 8 out of 10 patients who achieved clinical response (EASI-75*) with lebrikizumab monotherapy at 16 weeks maintained skin clearance at one year of treatment with the once every 2 weeks or 4 weeks regimen. Additionally, patients treated with lebrikizumab maintained itch relief across the two trials over the one-year period. These results build upon positive data from the 16-week, double-blind, placebo-controlled part of the ADvocate program.

AD, or atopic eczema, is a chronic, relapsing, heterogenous skin disease characterized by intense itching, dry skin, and inflammation that can be present on any part of the body. And lebrikizumab is a novel, monoclonal antibody (mAb) that binds to the interleukin-13 (IL-13) protein with high affinity to specifically prevent the formation of IL-13Rα1/IL-4Rα (Type 2 receptor) which blocks downstream signaling through the IL-13 pathway.3-7 IL-13 plays the central role in AD, promoting Type 2 inflammation that drives skin barrier dysfunction, itch, skin thickening, and infection.8-10

In ADvocate 1, 79% of patients who received lebrikizumab every four weeks and 79% of patients who received lebrikizumab every two weeks maintained 75% or greater skin improvement (EASI-75) at one year of treatment. And 85% of patients who received lebrikizumab every four weeks and 77% of patients who received lebrikizumab every two weeks maintained EASI-75 response in ADvocate 2 at one year of treatment.

The frequency of adverse events and the overall safety profile among these patients treated with lebrikizumab were consistent with the induction phase of the trials as well as previous lebrikizumab studies in AD. And no new safety signals were observed in this patient population.

With this data, Lilly plans to submit a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for lebrikizumab in AD in the second half of 2022, followed by submissions to other regulatory agencies around the world. Almirall also plans to submit these results this year to the European Medicines Agency (EMA) for authorization.

These studies are part of the comprehensive clinical development program for lebrikizumab in AD evaluating more than 2,000 patients. And the full one-year results from the Phase 3 monotherapy studies will be disclosed at upcoming congresses and in publications in 2022. Additional Phase 3 clinical trials are enrolling for lebrikizumab in AD.

Lilly has exclusive rights for the development and commercialization of lebrikizumab in the United States and the rest of the world outside Europe. Almirall has licensed the rights to develop and commercialize lebrikizumab for the treatment of dermatology indications, including AD, in Europe.


“Atopic dermatitis is a complex disease that requires personalized treatment approaches, including flexible dosing options for patients. In these studies, patients treated with lebrikizumab maintained skin clearance and lasting relief from intense itch at one year. We believe this supports the potential of lebrikizumab to become a first-line biologic and may support less frequent dosing. We look forward to providing an important new medicine and helping patients find the relief they so desperately seek from the varied and debilitating symptoms of this disease, contingent upon FDA approval.”

— Lotus Mallbris, M.D., Ph.D., vice president of global immunology development and medical affairs at Lilly

“ADvocate 1 and 2 results add to the exciting growing body of evidence from our Phase 3 clinical trial program and demonstrate that this medicine may provide much-needed relief for those seeking new treatment options. We look forward to continuing our collaboration with Lilly and advancing in our clinical program, aiming to obtain approval in the European Union.” 

— Karl Ziegelbauer, Ph.D., Almirall S.A.’s Chief Scientific Officer

Disclaimer: This content is intended for informational purposes. Before making any investment, you should do your own analysis.